SCHEMBL6078409

SCHEMBL6078409

CC(=O)Nc1ccc2c(OC(C)=O)cc(S(=O)(=O)Cl)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRA P11474 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FABP7 O15540 1/20 0.41
FABP3 P05413 1/20 0.41
FABP5 Q01469 1/20 0.41
ALDH1A1 P00352 4/20 0.39
TP53 P04637 1/20 0.39
RORC P51449 2/20 0.39
CDK1 P06493 1/20 0.39
PRMT1 Q99873 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31468113 1.00 ESRRA (0.42) ESRRAMEN1KMT2AFABP7FABP3
SCHEMBL31468121 0.80 PARG (0.44) MEN1KMT2AFABP7FABP3FABP5
SCHEMBL8690346 0.80 HTT (0.47) MEN1KMT2AALDH1A1TP53LMNA
SCHEMBL31468226 0.77 PARG (0.38) MEN1KMT2AFABP7FABP3FABP5
SCHEMBL949134 0.76 CA2 (0.53) MEN1KMT2AALDH1A1CA1CA2
SCHEMBL1770451 0.75 CA2 (0.51) MEN1KMT2AALDH1A1CA1CA2
SCHEMBL6124914 0.75 ALDH1A1 (0.44) MEN1KMT2AALDH1A1CDK1CA1
SCHEMBL4474912 0.73 KMT2A (0.45) MEN1KMT2AFABP7FABP3FABP5
SCHEMBL4480977 0.73 CASP6 (0.50) ESRRAMEN1KMT2AFABP7FABP3
SCHEMBL58191 0.70 CA1 (0.67) MEN1KMT2AALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071231-B2 Naphthalene ureas as glucose uptake enhancers TELIK, INC. (US) 2006-07-04 US disclosed
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP disclosed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US disclosed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US disclosed
EP-1181271-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS Telik, Inc. (US) 2002-02-27 EP disclosed
WO-2000071506-A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2001-09-20 WO disclosed
WO-2000071506-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK, INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers GPR119, SLC2A8, SLC2A1 ESRRA 378/4885MEN1 3696/4885KMT2A 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.